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Abstract
Sustained by its relative ease of assessment, carotid artery intima-media thickness (cIMT) has emerged as an
important surrogate marker of target organ damage in hypertensive heart disease over the last three decades.
However, the prognostic utility of cIMT in hypertensive heart disease differs depending on its application. This
review outlines cIMT and its prognostic utility among patients with hypertensive heart disease. It provides an
overview of limitations of cIMT and areas for future research.
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Background
Since the method was first proposed in the mid 1980s
[1], the ultrasonic evaluation of the combined intimal
and medial layers of the common carotid arteries have
garnered substantial scientific and clinical support as an
early, preclinical, vascular endpoint. Non-invasive, inex-
pensive, reproducible, and with prognostic utility among
the asymptomatic and diseased, it is increasingly being
used as a surrogate outcome or marker of target organ
damage, or used as a tool to base treatment strategies.
Although the use of carotid intima-media thickness
(cIMT) is pervasive, it is not without controversy.
Measured from B-mode ultrasound images as the
distance between the intima-lumen interface and the
media-adventitia interface (Fig. 1), there have been
substantial methodological differences among studies in
their approach to determining cIMT. These differences
include the artery examined (left, right, or both), arterial
segments to be examined (common carotid, internal
carotid, bifurcation), and the position of the measure-
ments within these segments, the phase of the cardiac
cycle, the walls (near or far), whether plaque is included
in the measurement, ultrasound technology, image
angle, and the approach to measurement (mean, max, or
mean of the max; average across all segments; type of
analysis software – semi-automated vs. manual) [2].
Different approaches to cIMT acquisition and measure-
ment have been shown to vary in terms of reproducibil-
ity, predictive utility, rate of change, susceptibility to
drug treatment, and the ability to obtain images for
measurement [3]. Recent progress toward standardising
approaches to image acquisition and measurement of
cIMT are proving useful [4–7] but more work is required
to ensure these approaches are well integrated and appro-
priate for different research areas and questions.
In the hypertensive patient, identification of asymp-
tomatic target organ damage may help inform treatment
decisions, and refine or reclassify an individual’s cardio-
vascular disease risk. cIMT is one surrogate marker of
target organ damage in the hypertensive patient that is
considered in guideline statements by several authorities.
The following will briefly overview the utility of cIMT
for the hypertensive patient.
Pathophysiology
Traditional ultrasound is unable to differentiate the
intima and media as separate entities [8]. Therefore, an
increased cIMT can be a result of a thicker intima,
media, or both. Processes involved in intimal thickening
are largely thought to mimic those in the pathogenesis
and progression of atherosclerotic plaques, whereas
hypertrophy of the media layer is primarily related to
hypertension unrelated to atherosclerosis [7, 9]. Although
thickening of the intima and media can occur by separate
pathways, the elastic carotid artery has a relatively small
media compared with muscular arteries and thus an
Correspondence: cmagnuss@utas.edu.au
1Menzies Institute for Medical Research, University of Tasmania, Private Bag
23, Hobart 7001, Tasmania, Australia
2Research Centre of Applied and Preventive Cardiovascular Medicine,
University of Turku, Turku, Finland
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Magnussen Clinical Hypertension  (2017) 23:7 
DOI 10.1186/s40885-017-0063-3
increased cIMT is thought to largely denote intimal rather
than medial thickening [10] and might explain the close
association between cIMT and atherosclerotic-related
cardiovascular events [11]. However, cIMT is considered a
separate phenotype to atherosclerotic plaque formation
and progression [7], with different clinical utility [12], and
as such, should be measured in areas free of plaque [4].
Prevalence
Prevalence data are not readily available because there is
no widely accepted cut-off for what constitutes an
adverse cIMT value. However, the European Society of
Hypertension (ESH)/European Society of Cardiology
(ESC) guidelines for the management of hypertension
suggest a value greater than 0.9 mm as being a conserva-
tive estimate of asymptomatic organ damage [13]. Before
criteria for what defines an abnormal cIMT can be estab-
lished, there is need for measurement consensus and
population reference values. In recent years there has
been a concerted effort to standardise approaches to
image acquisition and analysis with one example the
initiation and routine update to the Mannheim Consen-
sus statement [4]. Moreover, recent attempts to establish
cIMT reference values among diseased and healthy
populations have been notable, with the most compre-
hensive of these using data from approximately 25,000
individuals across 14 countries [14]. Interestingly, these
data showed that a cIMT value of greater than 0.9 mm
advocated by the ESH/ESC equates to values above the
90th percentile among the healthy, though very few less
than 70 years of age would meet this criterion level.
Because of the large age and sex effect on cIMT, sugges-
tion of race or ethnicity differences in cIMT [15–18], as
well as the variability introduced by different scanning
and measurement protocols, any cut-points, if they were
to be established, will likely need to recognise these
differences.
Clinical and prognostic significance
Since introduction of the technique, a plethora of data
has emerged showing associations between traditional
and emerging cardiovascular disease risk markers with
cIMT and that cIMT associates with disease elsewhere in
the vascular tree [19]. As with cardiovascular events, the
association between systolic blood pressure and cIMT
tends to be linear [20]. Irrespective of other risk factors,
children with elevated blood pressure have higher adult
cIMT than their counterparts [21], but those who are
able to amend their elevated blood pressure status in the
time between childhood and adulthood have a similar
prevalence of high cIMT in adulthood as those that
never had elevated blood pressure [22]. Clinical trials of
antihypertensive medications have shown cIMT to re-
gress or progress at a decreased rate among those
Fig. 1 B-mode ultrasound image of the common carotid artery (CCA): a border of carotid bulb widening (0 mm), (b) CCA far wall lumen-intima
interface, (c) media-adventitia interface. Definitions of the CCA segment for measurement differ depending on study and convention, but are
typically measured in the vicinity 0–10 mm proximal to the border of the bulb widening (a) (measurement area highlighted by yellow box). CCA
IMT is taken as the distance between (b) and (c)
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receiving best therapy compared with those on different
regimes or placebo [23–26].
There is substantial evidence that has demonstrated
the utility of cIMT to predict incident vascular events in
the asymptomatic [27] and diseased, including the
hypertensive patient, with a 1-standard deviation in-
crease in cIMT shown to associate with an 8% increased
risk of myocardial infarction and 19% increased risk of
stroke [28]. Nevertheless, the added value of cIMT mea-
surements over and above risk factors included in the
Framingham Risk Score, is inconsistent [29]. These in-
consistencies, and the prevalent measurement issues, were
the main weaknesses cited by the 2013 American College
of Cardiology/American Heart Association guideline on
the assessment of cardiovascular risk as reason not to
measure cIMT [30]. Indeed, the ESH/ESC in their 2013
guidelines [31] were more cautious in their advice for
cIMT measurement among hypertensive patients than in
their 2007 release [13]. For hypertensive patients, the cau-
tion appears warranted following recent results from the
IMPROVE (Immediate Management of the Patient with
Ruptured Aneurysm: Open Versus Endovascular repair)
cohort that showed area under the receiver operating
curve, or c-statistic, to predict myocardial infarction and
stroke was virtually unchanged when cIMT was added to
the Framingham Risk Score [28]. Net reclassification
improvement (NRI), which assesses the proportion of pa-
tients correctly reclassified to either a higher or lower risk,
with the addition of cIMT was also low (1.4%). There has
been suggestion that cIMT might benefit those of inter-
mediate risk based on the Framingham Risk Score, and
though IMPROVE found some statistical evidence of
improved reclassification among hypertensive patients,
the effect was again negligible (NRI = 5.6%).
Future research questions/needs
Measurement standardisation and the establishment of
population norms are needed, with strong recent pro-
gress being made in these areas. Progress is also being
made with respect to the clinical utility of cIMT to re-
classify risk among certain groups. Though the data sug-
gest that cIMT, if it were to be used, might be most
useful for reclassifying risk status amongst those of
intermediate risk of a future event, data are not available
as to whether the reclassification has a measurable impact
on morbidity or mortality or whether the costs associated
with scanning for cIMT outweigh the associated benefits,
if indeed this is shown to be the case. Clinical studies
should assess whether identifying an abnormal cIMT
among the hypertensive patient asymptomatic of other
target organ damage would improve treatment related
outcomes. Particularly among the hypertensive patient,
the utility of intima-media thickness measurements from
other arterial sites such as in more muscular arteries that
tend to have a thicker medial layer might provide add-
itional prognostic utility over cIMT [11]. Interest has been
gathering for the potential of cIMT to be used as a surro-
gate outcome for intervention trials, with a positive result
acting as a trigger to initiate large-scale and costly testing
of these interventions with the desired outcome of mor-
bidity and mortality [32]. The potential use of cIMT in the
paediatric setting to assess and monitor target organ dam-
age in high-risk children has been reported [3, 33–35].
However, the application of cIMT to the paediatric setting
has limitations that mimics those for adult populations –
namely, lack of normative values and best measurement
protocols, poor understanding of which cIMT segments
provide best diagnostic utility, and its cost-effectiveness
for routine monitoring.
Conclusion
Measures of cIMT are elevated amongst those with
hypertensive heart disease. Although individuals with a
higher cIMT are at increased risk of clinical cardiovascu-
lar outcomes, the prognostic utility of cIMT differs by
application and whether or not other risk factors are
considered in the prediction. Further standardisation in
measurement protocols, the subsequent establishment of
a clear level of cIMT beyond which indicates target
organ damage, and cost-effectiveness analysis of routine
scanning of cIMT may provide additional information
on the clinical usefulness of cIMT measurements for the
hypertensive patient.
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